BioSpace News Archive

Proteros biostructures GmbH announced that it has signed an agreement with AstraZeneca to jointly discover and develop novel small molecules for the potential treatment of various types of cancer.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced a new observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia.

Immune Therapeutics Inc. announced that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing Debt.

Data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress

World Health Organization Estimates up to 40 Percent of People Exposed to a Suspected Rabid Animal are Children Under 15 Years of Age

Renovacor, Inc., an early‑stage biotechnology company developing adeno-associated virus ‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor.

Sorrento Therapeutics, Inc. announced that the Mexican Comisión Federal para la Protección contra Riesgos Sanitarios, the health regulatory authority for Mexico, has listed COVI-STIX on its official government website list of rapid antigen tests approved for emergency use in Mexico.

Samsung Biologics, the world’s leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.

Repare Therapeutics Inc., a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, announced that members of its senior management team will participate in a fireside chat at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Eastern Time.

Approval based on CheckMate -743 trial results showing that Opdivo plus Yervoy significantly increased overall survival vs. standard-of-care chemotherapy – the first positive Phase 3 trial of an immunotherapy in this patient population